Introduction

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field.

Enanta is developing novel protease, NS5A, polymerase, and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA.


Enanta Pharmaceuticals is a privately held company with offices in Watertown, MA.

click here for more


Press Releases
March 2, 2010
Abbott and Enanta Announce Advancement of Hepatitis C Collaboration-- Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals

March 2, 2010
Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program

February 18, 2009
Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor

September 15, 2008
Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic with Activity Against Hospital and Community-Acquired MRSA


Archives